Myriad Genetics (MYGN) Earnings Analysis
Myriad Genetics (MYGN) has no confirmed upcoming earnings date. Last quarter (2026-02-23) it beat with EPS 0.04 USD vs -0.02 USD est (+300%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -1.31.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MYGN next report earnings?
No confirmed upcoming earnings date is currently scheduled for MYGN. This page updates as the calendar is published.
MYGN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-23 | 0.04 USD | -0.02 USD | +300% | Beat |
| 2025-11-03 | -0.13 USD | -0.01 USD | -1200% | Miss |
| 2025-02-24 | 0.03 USD | 0.03 USD | 0% | Beat |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
MYGN valuation and analyst view
| Trailing P/E | -1.31 |
|---|---|
| Trailing EPS | -4.26788 USD |
| Price / book | 1.57 |
| Dividend yield | 0.00% |
| Market cap | 0.54B |
| Analyst consensus | Hold (8 buy / 22 hold / 6 sell) |
| Avg price target | 7 USD |
Related research pages
Frequently asked questions
When is Myriad Genetics (MYGN)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for MYGN. This page updates as the calendar is published.
Did MYGN beat earnings last quarter?
In its 2026-02-23 report, MYGN posted EPS of 0.04 USD versus a -0.02 USD estimate — a beat of 300%.
What is MYGN's earnings track record?
Over the last 3 reported quarters with consensus data, MYGN beat estimates 2 times (67%).
What is MYGN's current P/E ratio and EPS?
MYGN trades at a trailing P/E of -1.31 on trailing EPS of -4.267876200640342 USD.
What do analysts rate MYGN?
Analyst consensus is "Hold" across 36 ratings (0 strong buy, 8 buy, 22 hold, 6 sell, 0 strong sell). Average 12-month price target: 7 USD.